STAT3 activation

References

• Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7:454 - 65; http://dx.doi.org/10.1038/nri2093; PMID: 17525754
   PubMed Web of Science ®Google Scholar
• Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19:2548 - 56; http://dx.doi.org/10.1038/sj.onc.1203551; PMID: 10851053
   PubMed Web of Science ®Google Scholar
• Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307:269 - 73; http://dx.doi.org/10.1126/science.1105166; PMID: 15653507
   PubMed Web of Science ®Google Scholar
• Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004; 22:503 - 29; http://dx.doi.org/10.1146/annurev.immunol.22.091003.090312; PMID: 15032587
   PubMed Web of Science ®Google Scholar
• Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 2005; 5:593 - 605; http://dx.doi.org/10.1038/nri1667; PMID: 16056253
   PubMed Web of Science ®Google Scholar
• Sun S, Steinberg BM. PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells. J Gen Virol 2002; 83:1651 - 8; PMID: 12075083
   PubMed Web of Science ®Google Scholar
• Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 2001; 409:349 - 54; http://dx.doi.org/10.1038/35053086; PMID: 11201744
   PubMed Web of Science ®Google Scholar
• Migone TS, Cacalano NA, Taylor N, Yi T, Waldmann TA, Johnston JA. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc Natl Acad Sci U S A 1998; 95:3845 - 50; http://dx.doi.org/10.1073/pnas.95.7.3845; PMID: 9520455
   PubMed Web of Science ®Google Scholar
• Schaper F, Gendo C, Eck M, Schmitz J, Grimm C, Anhuf D, et al. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem J 1998; 335:557 - 65; PMID: 9794795
   PubMed Web of Science ®Google Scholar
• Krasilnikov M, Ivanov VN, Dong J, Ronai Z. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 2003; 22:4092 - 101; http://dx.doi.org/10.1038/sj.onc.1206598; PMID: 12821943
   PubMed Web of Science ®Google Scholar
• Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 2007; 104:16158 - 63; http://dx.doi.org/10.1073/pnas.0702596104; PMID: 17911267
   PubMed Web of Science ®Google Scholar
• Daino H, Matsumura I, Takada K, Odajima J, Tanaka H, Ueda S, et al. Induction of apoptosis by extracellular ubiquitin in human hematopoietic cells: possible involvement of STAT3 degradation by proteasome pathway in interleukin 6-dependent hematopoietic cells. Blood 2000; 95:2577 - 85; PMID: 10753837
   PubMed Web of Science ®Google Scholar
• Bromberg J, Darnell JE Jr.. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19:2468 - 73; http://dx.doi.org/10.1038/sj.onc.1203476; PMID: 10851045
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798 - 809; http://dx.doi.org/10.1038/nrc2734; PMID: 19851315
   PubMed Web of Science ®Google Scholar
• Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11:595 - 6; http://dx.doi.org/10.1038/nm0605-595; PMID: 15937466
   PubMed Web of Science ®Google Scholar
• Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15:91 - 102; http://dx.doi.org/10.1016/j.ccr.2009.01.002; PMID: 19185844
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15:103 - 13; http://dx.doi.org/10.1016/j.ccr.2009.01.001; PMID: 19185845
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci 2009; 1171:59 - 76; http://dx.doi.org/10.1111/j.1749-6632.2009.04911.x; PMID: 19723038
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565 - 70; http://dx.doi.org/10.1126/science.1203486; PMID: 21436444
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480 - 9; http://dx.doi.org/10.1038/nature10673; PMID: 22193102
   PubMed Web of Science ®Google Scholar
• Shiku H. Importance of CD4+ helper T-cells in antitumor immunity. Int J Hematol 2003; 77:435 - 8; http://dx.doi.org/10.1007/BF02986610; PMID: 12841380
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960 - 4; http://dx.doi.org/10.1126/science.1129139; PMID: 17008531
   PubMed Web of Science ®Google Scholar
• Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marrogi OL, et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997; 74:492 - 501; http://dx.doi.org/10.1002/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z; PMID: 9355970
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94:275 - 80; http://dx.doi.org/10.1038/sj.bjc.6602934; PMID: 16421594
   PubMed Web of Science ®Google Scholar
• Tüting T, Storkus WJ, Lotze MT. Gene-based strategies for the immunotherapy of cancer. J Mol Med (Berl) 1997; 75:478 - 91; http://dx.doi.org/10.1007/s001090050133; PMID: 9253711
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54:721 - 8; http://dx.doi.org/10.1007/s00262-004-0653-2; PMID: 16010587
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263 - 71; http://dx.doi.org/10.1158/0008-5472.CAN-10-2907; PMID: 21303976
   PubMed Web of Science ®Google Scholar
• Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655 - 69; http://dx.doi.org/10.1016/S0092-8674(00)80702-3; PMID: 10761931
   PubMed Web of Science ®Google Scholar
• Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89:587 - 96; http://dx.doi.org/10.1016/S0092-8674(00)80240-8; PMID: 9160750
   PubMed Web of Science ®Google Scholar
• Owaki T, Asakawa M, Morishima N, Mizoguchi I, Fukai F, Takeda K, et al. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J Immunol 2008; 180:2903 - 11; PMID: 18292512
   PubMed Web of Science ®Google Scholar
• Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci U S A 2003; 100:15047 - 52; http://dx.doi.org/10.1073/pnas.2536517100; PMID: 14657353
   PubMed Web of Science ®Google Scholar
• Chen Z, O’Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008; 41:87 - 102; http://dx.doi.org/10.1007/s12026-007-8014-9; PMID: 18172584
   PubMed Web of Science ®Google Scholar
• van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5:549 - 53; http://dx.doi.org/10.1038/nrrheum.2009.179; PMID: 19798029
   PubMed Web of Science ®Google Scholar
• Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 2010; 184:1630 - 41; http://dx.doi.org/10.4049/jimmunol.0902813; PMID: 20026736
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126:1121 - 33; http://dx.doi.org/10.1016/j.cell.2006.07.035; PMID: 16990136
   PubMed Web of Science ®Google Scholar
• Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, et al. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007; 179:4313 - 7; PMID: 17878325
   PubMed Web of Science ®Google Scholar
• Nishihara M, Ogura H, Ueda N, Tsuruoka M, Kitabayashi C, Tsuji F, et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int Immunol 2007; 19:695 - 702; http://dx.doi.org/10.1093/intimm/dxm045; PMID: 17493959
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8:967 - 74; http://dx.doi.org/10.1038/ni1488; PMID: 17581537
   PubMed Web of Science ®Google Scholar
• Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 2007; 282:9358 - 63; http://dx.doi.org/10.1074/jbc.C600321200; PMID: 17277312
   PubMed Web of Science ®Google Scholar
• Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26:371 - 81; http://dx.doi.org/10.1016/j.immuni.2007.02.009; PMID: 17363300
   PubMed Web of Science ®Google Scholar
• Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008; 28:29 - 39; http://dx.doi.org/10.1016/j.immuni.2007.11.016; PMID: 18164222
   PubMed Web of Science ®Google Scholar
• Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012; 36:362 - 73; http://dx.doi.org/10.1016/j.immuni.2011.12.019; PMID: 22406269
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature 2010; 467:967 - 71; http://dx.doi.org/10.1038/nature09447; PMID: 20962846
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101:455 - 8; http://dx.doi.org/10.1016/S0092-8674(00)80856-9; PMID: 10850488
   PubMed Web of Science ®Google Scholar
• Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389 - 400; PMID: 12093005
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875 - 86; http://dx.doi.org/10.1084/jem.20030152; PMID: 14676299
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127:759 - 67; PMID: 20518016
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942 - 9; http://dx.doi.org/10.1038/nm1093; PMID: 15322536
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373 - 80; http://dx.doi.org/10.1200/JCO.2006.05.9584; PMID: 17135638
   PubMed Web of Science ®Google Scholar
• Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer 2008; 44:1875 - 82; http://dx.doi.org/10.1016/j.ejca.2008.05.017; PMID: 18617393
   PubMed Web of Science ®Google Scholar
• Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108:1571 - 9; http://dx.doi.org/10.1182/blood-2006-02-004747; PMID: 16645171
   PubMed Web of Science ®Google Scholar
• Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007; 445:766 - 70; http://dx.doi.org/10.1038/nature05479; PMID: 17220876
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15:114 - 23; http://dx.doi.org/10.1016/j.ccr.2008.12.018; PMID: 19185846
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009; 326:986 - 91; http://dx.doi.org/10.1126/science.1172702; PMID: 19797626
   PubMed Web of Science ®Google Scholar
• Wuest TY, Willette-Brown J, Durum SK, Hurwitz AA. The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol 2008; 84:973 - 80; http://dx.doi.org/10.1189/jlb.1107778; PMID: 18653463
   PubMed Web of Science ®Google Scholar
• Huber M, Steinwald V, Guralnik A, Brüstle A, Kleemann P, Rosenplänter C, et al. IL-27 inhibits the development of regulatory T cells via STAT3. Int Immunol 2008; 20:223 - 34; http://dx.doi.org/10.1093/intimm/dxm139; PMID: 18156621
   PubMed Web of Science ®Google Scholar
• Xu L, Kitani A, Stuelten C, McGrady G, Fuss I, Strober W. Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity 2010; 33:313 - 25; http://dx.doi.org/10.1016/j.immuni.2010.09.001; PMID: 20870174
   PubMed Web of Science ®Google Scholar
• Laurence A, Amarnath S, Mariotti J, Kim YC, Foley J, Eckhaus M, et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 2012; 37:209 - 22; http://dx.doi.org/10.1016/j.immuni.2012.05.027; PMID: 22921119
   PubMed Web of Science ®Google Scholar
• Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 2009; 58:1023 - 32; http://dx.doi.org/10.1007/s00262-008-0618-y; PMID: 19002459
   PubMed Web of Science ®Google Scholar
• Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222:162 - 79; http://dx.doi.org/10.1111/j.1600-065X.2008.00602.x; PMID: 18364001
   PubMed Web of Science ®Google Scholar
• Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164:6166 - 73; PMID: 10843666
   PubMed Web of Science ®Google Scholar
• Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008; 13:453 - 61; http://dx.doi.org/10.2741/2692; PMID: 17981560
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4:71 - 8; http://dx.doi.org/10.1038/nrc1256; PMID: 14708027
   PubMed Web of Science ®Google Scholar
• Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42:717 - 27; http://dx.doi.org/10.1016/j.ejca.2006.01.003; PMID: 16520032
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66:605 - 12; http://dx.doi.org/10.1158/0008-5472.CAN-05-4005; PMID: 16423985
   PubMed Web of Science ®Google Scholar
• Jenkins BJ, Grail D, Inglese M, Quilici C, Bozinovski S, Wong P, et al. Imbalanced gp130-dependent signaling in macrophages alters macrophage colony-stimulating factor responsiveness via regulation of c-fms expression. Mol Cell Biol 2004; 24:1453 - 63; http://dx.doi.org/10.1128/MCB.24.4.1453-1463.2004; PMID: 14749363
   PubMed Web of Science ®Google Scholar
• Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003; 19:425 - 36; http://dx.doi.org/10.1016/S1074-7613(03)00232-2; PMID: 14499117
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y, et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 2009; 69:2497 - 505; http://dx.doi.org/10.1158/0008-5472.CAN-08-3031; PMID: 19258507
   PubMed Web of Science ®Google Scholar
• Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, et al. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett 2010; 131:126 - 30; http://dx.doi.org/10.1016/j.imlet.2010.03.004; PMID: 20346983
   PubMed Web of Science ®Google Scholar
• Sun Z, Yao Z, Liu S, Tang H, Yan X. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology 2006; 211:199 - 209; http://dx.doi.org/10.1016/j.imbio.2005.11.004; PMID: 16530087
   PubMed Web of Science ®Google Scholar
• Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216:15 - 24; http://dx.doi.org/10.1002/path.2370; PMID: 18553315
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Komohara Y, Ikeda T, Takeya M. Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Sci 2011; 102:206 - 11; http://dx.doi.org/10.1111/j.1349-7006.2010.01772.x; PMID: 21073634
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Komohara Y, Kudo R, Tsurushima K, Ohnishi K, Ikeda T, et al. Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3. Oncol Rep 2011; 26:1533 - 7; PMID: 21922144
   PubMed Web of Science ®Google Scholar
• Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010; 101:1913 - 9; http://dx.doi.org/10.1111/j.1349-7006.2010.01614.x; PMID: 20545696
   PubMed Web of Science ®Google Scholar
• Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008; 118:3367 - 77; http://dx.doi.org/10.1172/JCI35213; PMID: 18776941
   PubMed Web of Science ®Google Scholar
• Domínguez-Soto A, Sierra-Filardi E, Puig-Kröger A, Pérez-Maceda B, Gómez-Aguado F, Corcuera MT, et al. Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J Immunol 2011; 186:2192 - 200; http://dx.doi.org/10.4049/jimmunol.1000475; PMID: 21239715
   PubMed Web of Science ®Google Scholar
• Hiwatashi K, Tamiya T, Hasegawa E, Fukaya T, Hashimoto M, Kakoi K, et al. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction. Cancer Lett 2011; 308:172 - 80; http://dx.doi.org/10.1016/j.canlet.2011.04.024; PMID: 21624767
   PubMed Web of Science ®Google Scholar
• Li Y, Cai L, Wang H, Wu P, Gu W, Chen Y, et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene 2011; 30:3887 - 99; http://dx.doi.org/10.1038/onc.2011.112; PMID: 21499310
   PubMed Web of Science ®Google Scholar
• Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005; 174:3925 - 31; PMID: 15778348
   PubMed Web of Science ®Google Scholar
• Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48 - 54; http://dx.doi.org/10.1038/nm976; PMID: 14702634
   PubMed Web of Science ®Google Scholar
• Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 2010; 12:1113 - 25; http://dx.doi.org/10.1093/neuonc/noq082; PMID: 20667896
   PubMed Web of Science ®Google Scholar
• Crowley M, Inaba K, Steinman RM. Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins. J Exp Med 1990; 172:383 - 6; http://dx.doi.org/10.1084/jem.172.1.383; PMID: 1694226
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271 - 96; http://dx.doi.org/10.1146/annurev.iy.09.040191.001415; PMID: 1910679
   PubMed Web of Science ®Google Scholar
• Laouar Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 2003; 19:903 - 12; http://dx.doi.org/10.1016/S1074-7613(03)00332-7; PMID: 14670306
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11:1314 - 21; http://dx.doi.org/10.1038/nm1325; PMID: 16288283
   PubMed Web of Science ®Google Scholar
• Iwata-Kajihara T, Sumimoto H, Kawamura N, Ueda R, Takahashi T, Mizuguchi H, et al. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol 2011; 187:27 - 36; http://dx.doi.org/10.4049/jimmunol.1002067; PMID: 21632716
   PubMed Web of Science ®Google Scholar
• Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, et al. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res 2010; 70:7455 - 64; http://dx.doi.org/10.1158/0008-5472.CAN-10-0736; PMID: 20841481
   PubMed Web of Science ®Google Scholar
• Park SJ, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa S, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004; 173:3844 - 54; PMID: 15356132
   PubMed Web of Science ®Google Scholar
• Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 2007; 178:6867 - 75; PMID: 17513735
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004; 172:464 - 74; PMID: 14688356
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65:9525 - 35; http://dx.doi.org/10.1158/0008-5472.CAN-05-0529; PMID: 16230418
   PubMed Web of Science ®Google Scholar
• Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005; 175:4338 - 46; PMID: 16177074
   PubMed Web of Science ®Google Scholar
• Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007; 67:5479 - 88; http://dx.doi.org/10.1158/0008-5472.CAN-06-3963; PMID: 17545630
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21:11 - 9; http://dx.doi.org/10.1016/j.cytogfr.2009.11.005; PMID: 20018552
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67:425 - , author reply 426; http://dx.doi.org/10.1158/0008-5472.CAN-06-3037; PMID: 17210725
   PubMed Web of Science ®Google Scholar
• Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14:408 - 19; http://dx.doi.org/10.1016/j.ccr.2008.10.011; PMID: 18977329
   PubMed Web of Science ®Google Scholar
• Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166:678 - 89; PMID: 11123353
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49 - 59; http://dx.doi.org/10.1007/s00262-008-0523-4; PMID: 18446337
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828 - 35; http://dx.doi.org/10.1038/nm1609; PMID: 17603493
   PubMed Web of Science ®Google Scholar
• Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010; 120:457 - 71; PMID: 20093776
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162 - 74; http://dx.doi.org/10.1038/nri2506; PMID: 19197294
   PubMed Web of Science ®Google Scholar
• Zhang H, Nguyen-Jackson H, Panopoulos AD, Li HS, Murray PJ, Watowich SS. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 2010; 116:2462 - 71; http://dx.doi.org/10.1182/blood-2009-12-259630; PMID: 20581311
   PubMed Web of Science ®Google Scholar
• Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32:790 - 802; http://dx.doi.org/10.1016/j.immuni.2010.05.010; PMID: 20605485
   PubMed Web of Science ®Google Scholar
• Hirai H, Zhang P, Dayaram T, Hetherington CJ, Mizuno S, Imanishi J, et al. C/EBPbeta is required for ‘emergency’ granulopoiesis. Nat Immunol 2006; 7:732 - 9; http://dx.doi.org/10.1038/ni1354; PMID: 16751774
   PubMed Web of Science ®Google Scholar
• Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693 - 701; http://dx.doi.org/10.4049/jimmunol.0900092; PMID: 19380816
   PubMed Web of Science ®Google Scholar
• Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235 - 49; http://dx.doi.org/10.1084/jem.20080132; PMID: 18809714
   PubMed Web of Science ®Google Scholar
• Mankan AK, Greten FR. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin Investig Drugs 2011; 20:1263 - 75; http://dx.doi.org/10.1517/13543784.2011.601739; PMID: 21751940
   PubMed Web of Science ®Google Scholar